Swiss Life Sciences Group Develops Cannabis Genetics for Healthcare
Cannabis Law Report
AUGUST 20, 2021
SLSG and its Swiss subsidiary, Savim SA , are developing specific proprietary strains of cannabis, with a focus on various areas, but particularly on future medical treatments for a variety of illnesses and diseases, including epilepsy, autism, and the different stages of COVID-19.
Let's personalize your content